Concepedia

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study

Alex Z. Fu, Stephen S. Johnston, Ameen Ghannam, Katherine Tsai, Katherine Cappell, Robert Fowler, Ellen Riehle, Ashley L. Cole, Iftekhar Kalsekar, John J. Sheehan

Diabetes Care · 2016 · 77 citations · 27 references

DOI

Abstract

In patients with type 2 diabetes, there was no association between hHF, or other selected cardiovascular outcomes, and treatment with a DPP-4i relative to SU or treatment with saxagliptin relative to sitagliptin.

References

27

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong et al. · New England Journal of Medicine · 2015 · 2.5K citations · Full text

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · The Lancet · 2009 · 1.4K citations

, , +10

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

Curtis L. Meinert, Genell L Knatterud, Thaddeus E. Prout et al. · PubMed · 1970 · 988 citations

, , +11

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Benjamin M. Scirica, Eugene Braunwald, Itamar Raz et al. · Circulation · 2014 · 718 citations